Funds

Discover the investment opportunities at Danube BioVentures. Our specialised funds, CEBINA Bridge Capital and DanubeNeuro, are dedicated to transforming innovative ideas into successful commercial ventures.
TAG Therapeutics, our first spin-off, showcases our ability to identify and nurture high-potential biotech projects.
Learn more about our investment strategy, partners and goals.
↓ Learn more about Fund II: DanubeNeuro

↓ Learn more about Fund I: CEBINA Bridge Capital

FUND II: DanubeNeuro
Financing the DanubeNeuro Programme

The longevity and neurodegeneration industry generated $25.1 billion in 2020 and is expected to reach $44.2 billion by 2030. To capitalise on this expanding market, DanubeNeuro is building a worldwide portfolio of new life science ventures focused on delivering innovative therapeutics, diagnostics, biomarkers, and imaging platforms in the field of neurodegeneration, as well as solutions to increase health span and resilience in the ageing population.
DanubeNeuro has entered into a collaboration agreement with CEBINA, the experienced Vienna-based biotech incubator, accelerator, and product development and research company. CEBINA identifies and evaluates research projects with product development potential from universities and academic research institutes for further investment. Selected projects receive an initial award of up to one million EUR. When being commercialised further into new SPVs or by out-licensing to pharma, funding can also include IND-enabling studies and phase 1 and phase 2 clinical trials.

↑ Image

↑ Image

↑ Image

CEBINA - Central European Biotech Incubator and Accelerator.

CEBINA - Central European Biotech Incubator and Accelerator.

CEBINA - Central European Biotech Incubator and Accelerator.

With this strategic foundation, the DanubeNeuro programme is set to unlock the vast market opportunities in the fight against neurodegeneration and enhance health outcomes in the ageing population.

Fund I: Cebina Bridge Capital (closed)
Financing the Danube Labs Program

CEBINA Bridge Capital and the associated DanubeLabs Programme enable the identification and support of pharmaceutical drug discovery projects originating from universities, research institutes, and other entities in Central and Eastern Europe.
The first spin-off resulting from these efforts is TAG Therapeutics, developed in cooperation with world-renowned scientist Fabrizio D’Adda di Fagagna from IFOM (AIRC Institute of Molecular Oncology) in Milan.
In the CEE region, historically, university institutions have focused on teaching and basic research, while the commercial exploitation of research results has often taken a back seat. Even today, this region offers many treasures in basic research – opportunities waiting to be discovered by experts for development.
In this context, DanubeLabs works with two highly renowned cooperation partners: the Vienna-based biotech specialist CEBINA and Evotec, a global leader in drug discovery.
CEBINA is an Austrian biotech incubator, accelerator, and product development and research company. With a strong network in the CEE region, CEBINA is responsible for identifying and assessing promising drug discovery projects. CEBINA also supervises the investments, protecting and maintaining intellectual property rights.
Evotec is a pioneering force in drug discovery, providing research and drug development services to the pharmaceutical and biotechnology industries, and conducting research and development activities for both internal and partnered drug development programmes. Evotec provides discovery, research, preclinical, development, and other related services to CEBINA in support of identified high-potential projects.
Through this cooperation, DanubeLabs emerges as a high-profile initiative to foster and commercialise innovations from the CEE region, making them beneficial via new SPVs or licence deals, and ultimately accessible to patients.

Portfolio

Portfolio

Portfolio

Our Mission

Our Mission

Our Mission